STEMI Clinical Trial
Official title:
Effectiveness and Safety of Early Administration of Heparin at First Medical Contact for STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: a Multicenter, Prospective, Randomized, Controlled Study
Heparin is the first choice of anticoagulation drug for primary PCI of STEMI patients. However, the priority of use of hepairn in first medical contact or in Cathlab has not yet studied. Previous study revealed early use of antithrombotic drugs could improve patient's survival. Here we supposed that use of heparin at first medical contact could increase the TIMI flow 3 grade ratio in STEMI patients and improve patient's survival and/or reduce MACE rather than in Cathlab.
This study will recruit 944 STEMI patients undergoing primary PCI with the symptom onset within 12 hours in 36 hospitals in Hubei Province, China. The patients will be 1:1 randomly assigned to the intervention group (IG) and control group (CG). Patients in IG will be intravenously administrated with sodium heparin (100U/Kg) at first medical contact, while patients in CG will be administrated with sodium heparin (100U/Kg) through catheter sheath in the CathLab. Inclusion Criteria: STEMI patient; Symptom onset in 12 hours; Intended to perform PPCI. Exclusion Criteria:Active bleeding; Life expectancy less than 1 year; History of heparin-induced thrombocytopenia; Mechanical complication of MI (VSR, acute MR); History of CABG; On Coagulation drugs; CPR before randomization; Pregnant or lactating woman;Refused to sign the Informed Consent Form. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT02871622 -
BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM
|
N/A | |
Completed |
NCT01325116 -
Delayed Educational Reminders in Acute Myocardial Infarction (MI)
|
N/A | |
Completed |
NCT01452139 -
Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI)
|
Phase 2/Phase 3 | |
Completed |
NCT01625104 -
Randomized Trial of a Quality Improvement Intervention to Decrease D2B Time in Primary PCI for AMI
|
N/A | |
Completed |
NCT04023266 -
A Pilot Randomized Controlled Trial of Intravenous N-acetyl Cysteine in STEMI
|
Phase 2 | |
Completed |
NCT02170103 -
Microvascular Recovery With Ultrasound in Myocardial Infarction (MRUSMI) Post PCI Trial
|
N/A | |
Completed |
NCT03103620 -
Safety and Effectiveness Evaluation of COBRA PzF Coronary Stent System: A Post Marketing Observational Registry
|
||
Not yet recruiting |
NCT05975567 -
Deploying Novel Imaging Modalities Towards a Three-dimensional (3D) CARDIOvascular PATHology
|
||
Enrolling by invitation |
NCT03328156 -
Erectile Dysfunction After Percutaneous Coronary Intervention Versus the Thrombolytic Therapy in Acute ST Elevation Myocardial Infarction
|
N/A | |
Completed |
NCT04017169 -
No Reflow Phenomenon Incidence and Predictors
|
||
Completed |
NCT03470441 -
A Study of Acute Myocardial Infarction Using FDY-5301
|
Phase 2 | |
Active, not recruiting |
NCT01433627 -
Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX
|
Phase 3 | |
Completed |
NCT01197742 -
Sweetheart-Register: Risk Management of Diabetics With Acute Myocardial Infarction
|
N/A | |
Terminated |
NCT03439150 -
Resistance STEMI Study
|
N/A | |
Recruiting |
NCT03998319 -
A Study of Low-dose Intracoronary Thrombolytic Therapy in STEMI (Heart Attack) Patients.
|
Phase 3 | |
Not yet recruiting |
NCT05974930 -
Intravascular ULTRAsound-Guided PCI in Patients With ST-Elevation Myocardial Infarction
|
||
Active, not recruiting |
NCT03102723 -
Platelet Inhibition to Target Reperfusion Injury
|
Phase 2 | |
Completed |
NCT03930589 -
Remote Ischemic Conditioning in STEMI to Decrease Infarct Size
|
N/A | |
Not yet recruiting |
NCT04912167 -
The Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial Infarction
|
Phase 3 | |
Completed |
NCT02942550 -
Methylnaltrexone as a Method to Improve Ticagrelor Uptake in Morphine Treated STEMI Patients
|
Phase 4 |